Smoother-Looking Skin
Intradermal Skinvive may be used to improve skin smoothness of the cheeks in adults over 21.
Injectable skin refinement for patients who want smoother, more hydrated-looking skin while keeping their facial features completely familiar.
Skinvive uses hyaluronic acid microdroplets to improve skin quality rather than create traditional facial volume.
At Dermatology Circle, treatment begins with an assessment of your skin, facial anatomy and overall cosmetic goals before deciding whether Skinvive is the right tool.


Skinvive belongs to the Juvéderm hyaluronic acid family, but its aesthetic goal is skin refinement.
Small amounts of product are placed within the skin to support smoothness and a more hydrated, supple appearance.
Traditional fillers may be selected when the concern is structural support, contour or facial volume. Skinvive is used when the skin itself is the treatment priority.
Skinvive can now be considered for two distinct skin-quality concerns.
The original indication focuses on cheek smoothness. In 2026, the FDA indication expanded to include selected neck lines and overall neck appearance.
Intradermal Skinvive may be used to improve skin smoothness of the cheeks in adults over 21.
Skinvive may also be used intradermally and/or subdermally to reduce neck lines and improve neck appearance.
Skinvive may also be considered within a broader physician-directed neck rejuvenation plan .
Skinvive is designed for subtle improvement. The treatment should enhance how skin looks rather than dramatically alter facial structure.
Skin can appear smoother and more polished after treatment.
Hyaluronic acid supports hydration within treated skin.
Improvement is designed to look natural rather than obviously cosmetic.
Selected neck lines can now be addressed within an FDA-approved indication.
Skin-quality results can be subtle, which makes consistent clinical photography particularly important.
Individual results vary.
In this documented case, the whole face was treated with two syringes of Skinvive. The follow-up photograph was taken two weeks after treatment.
Product amount and individual response vary.
Standardized photography matters. Consistent lighting and positioning help distinguish real improvement from photographic variation.
View More Cosmetic ResultsThe treatment is most useful when skin quality is genuinely the primary concern.
Volume loss, significant laxity, pigmentation, vascular redness and surface texture may require different treatment strategies.
For example, patients concerned about laxity may benefit more from skin tightening , while persistent facial redness may require dedicated rosacea and vascular treatment .
Skinvive uses small deposits of modified hyaluronic acid to support skin smoothness and quality.
This placement strategy differs from the way many traditional fillers are used for volume or structural support.

Skinvive is delivered through multiple small injections across the selected area.
Distribution, injection depth and product amount are individualized rather than applied as a one-size-fits-all protocol.
Skinvive contains lidocaine. Temporary bumps, swelling, redness or bruising may occur, but prolonged visible downtime is not typical for many patients.
Skinvive is intended to create subtle improvement rather than dramatic facial change.
Clinical studies supporting its approved indications have demonstrated improvement lasting for several months after optimal treatment. Individual response varies.
The best cosmetic plan starts by understanding what is changing — not by choosing a syringe.
At Dermatology Circle, cosmetic treatment is planned around skin quality, facial structure, movement, volume, laxity and previous procedures.
Skinvive may be an elegant option when smoothness and skin quality are the priority. When another modality is more appropriate, the treatment plan changes.
Skin aging rarely has only one component.
Depending on the patient, a cosmetic plan may separately address hydration, movement, volume, laxity, redness, pigmentation or surface texture.
Skinvive can complement other procedures when each treatment has a clear role.
Skinvive remains an injectable hyaluronic acid medical treatment.
Temporary redness, swelling, tenderness, firmness, small bumps, bruising, itching or discoloration may occur around injection sites.
As with other injectable fillers, accidental injection into a blood vessel can lead to serious complications.
Active inflammation, rash, sores or infection in the intended area should be evaluated before injection.
Private, physician-led cosmetic dermatology for patients who value natural results, discretion and continuity of care.
A consultation is also the right time to determine whether Skinvive, another injectable or a different modality best addresses your concern.
Skinvive is a hyaluronic acid injectable within the Juvéderm family. Its aesthetic role differs from traditional volumizing filler because it is used primarily to improve skin smoothness and quality.
Clinical studies have demonstrated improvement lasting for several months after optimal treatment. Individual duration and maintenance needs vary.
Yes. In 2026, the FDA indication expanded to include intradermal and/or subdermal injection to reduce neck lines and improve neck appearance in adults over 21.
The lips are not part of the current FDA-approved Skinvive indications. Treatment outside the approved indication requires individualized medical judgment.
The under-eye area is not an FDA-approved Skinvive indication and is anatomically sensitive. Treatment selection should begin with evaluation of the actual concern.
Skinvive is a hyaluronic acid product. Hyaluronidase may be considered in selected clinical circumstances when medically appropriate.
They address different concerns. Neuromodulators target selected expression-related lines, while Skinvive focuses on skin quality. Both may be part of one treatment plan when appropriate.
Skinvive is a hyaluronic acid injectable used for skin smoothness and quality. Sculptra is a PLLA biostimulatory injectable that stimulates collagen over time. Their mechanisms and goals differ.
Both may be discussed as skin-quality injectables, but Profhilo is not FDA-approved for aesthetic use in the United States. Skinvive has specific FDA-approved U.S. indications.
Temporary injection-site swelling, redness, tenderness, small bumps or bruising can occur. Many patients do not require prolonged visible recovery.
Cost depends on treatment area, product amount and the individualized plan. Exact pricing is reviewed after determining what should be treated and how much product is appropriate.
Start with a physician assessment of your skin, facial anatomy and goals. If Skinvive fits the plan, treatment follows.